Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financi...(income per common share ...),Health

Date:2/27/2009

income per common share $1.73 to $1.81 Upfront and milestone payments to partners $0.26 $0.26 Amortization of commercial intangible assets $0.48 $0.48 Indevus transaction and separation costs $0.23 $0.23 Interest expense adjustment for APB 14-1 $0.12 $0.12 Tax effect of pre-tax adjustments at the applicable tax rates and certain other expected cash tax savings as a result of the Indevus acquisition ($0.23) ($0.23) Diluted adjusted income per common share guidance $2.59 to $2.67

The company's guidance is being issued based on certain assumptions including:

• Adjusted effective tax rate of approximately 33.6% in 2009;
• Weighted average number of common shares outstanding of 117.1 million shares for the year ended December 31, 2009;
• The February 23, 2009 acquisition date of Indevus Pharmaceuticals, Inc.; and
• Certain of the above amounts are based on preliminary estimates and there can be no assurance that Endo will achieve these results.

For an explanation of Endo's reasons for using non-GAAP measures, see Endo's Current Report on Form 8-K filed today with the Securities and Exchange Commission.

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of post
'/>"/>

SOURCE Endo Pharmaceuticals Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine news :

1. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
2. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
3. Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children
4. Endo Pharmaceuticals Appoints William Montague to Board of Directors
5. Access Pharmaceuticals Closes Acquisition of MacroChem Corp.
6. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
7. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
8. Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television
9. Update: Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
10. Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
11. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results